Oncternal Therapeutics Azioni (NASDAQ: ONCT)

Ultime notizie per Oncternal Therapeutics (NASDAQ:ONCT) Azioni

Oncternal Therapeutics

Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.

Oncternal Therapeutics, Inc. - Common Stock

Oncternal Therapeutics Inc

Investors with a lot of money to spend have taken a bearish stance on ASML Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ASML, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 40 uncommon options trades for ASML Holding.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 50%, bearish.
Out of all of the special options we uncovered, 17 are puts, for a total amount of $1,038,822, and 23 are calls, for a total amount of $1,378,563.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $600.0 to $960.0 for ASML Holding over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for ASML Holding's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across ASML Holding's significant trades, within a strike price range of $600.0 to $960.0, over the past month.
<h3>ASML Holding Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732293644_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASML</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$108.4</td>
<td>$105.9</td>
<td>$108.4</td>
<td>$700.00</td>
<td>$227.6K</td>
<td align="right">604</td>
<td align="right">21</td>
</tr>
<tr>
<td>ASML</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$39.0</td>
<td>$38.4</td>
<td>$38.58</td>
<td>$640.00</td>
<td>$192.9K</td>
<td align="right">648</td>
<td align="right">100</td>
</tr>
<tr>
<td>ASML</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$89.7</td>
<td>$87.0</td>
<td>$89.7</td>
<td>$750.00</td>
<td>$188.3K</td>
<td align="right">95</td>
<td align="right">21</td>
</tr>
<tr>
<td>ASML</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$48.8</td>
<td>$48.5</td>
<td>$48.8</td>
<td>$700.00</td>
<td>$102.4K</td>
<td align="right">269</td>
<td align="right">23</td>
</tr>
<tr>
<td>ASML</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$27.4</td>
<td>$25.4</td>
<td>$25.4</td>
<td>$700.00</td>
<td>$93.9K</td>
<td align="right">932</td>
<td align="right">38</td>
</tr>
</tbody>
</table>

<h3>About ASML Holding</h3>
ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photo mask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a high portion of the cost of making cutting-edge chips. ASML outsources the manufacturing of most of its parts, acting like an assembler. ASML's main clients are TSMC, Samsung, and Intel.
Following our analysis of the options activities associated with ASML Holding, we pivot to a closer look at the company's own performance.
<h3>ASML Holding's Current Market Status</h3>
<ul>
<li>Trading volume stands at 482,394, with ASML's price down by -0.55%, positioned at $668.45.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 68 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest ASML Holding options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

ASML

ASML Holding's Options Frenzy: What You Need to Know

News

IPOs

Trading Ideas

CASK

Heritage Distilling Opens For Trade At $4/Share; IPO Priced At $4/Share On 1.6875M Shares

Oppenheimer analyst Mitchel Penn maintains Oaktree Specialty Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCSL#NASDAQ">OCSL</a>) with a Perform and maintains $18 price target.

Price Target

Analyst Ratings

OCSL

Oppenheimer Maintains Perform on Oaktree Specialty Lending, Maintains $18 Price Target

QMMM

QMMM Shares Resume Trade

Nano Labs Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) shares rose on Friday after the company launched its second-generation<a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener"> V Series crypto mining products.</a>
Powered by the advanced Cuckoo 3.0 chips, the V2, V2H, and V2X models set new benchmarks for performance and energy <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42136093/nano-labs-launches-second-generation-v-series-with-5x-power-efficiency-boost" rel="noreferrer noopener">efficiency in the crypto-mining industry.</a>
The V2H and V2X models deliver nearly four times the computing power of their first-generation counterparts, significantly enhancing power efficiency.
This makes the V2 Series one of the most efficient mining solutions on the market. In addition to performance improvements, the V2 Series features upgraded hardware, enhanced heat dissipation systems, and better resistance to high temperatures, ensuring more stable and cost-effective operation.
Also Read:<a target="_blank" href="https://www.benzinga.com/news/econ-s/24/11/42138717/dollar-hits-2-year-highs-as-europes-recession-signals-spark-euro-pound-sell-offs" rel="noreferrer noopener"> Dollar Hits 2-Year High As European Recession Fears Hammer Euro, Pound</a>
Nano Labs, which began crypto mining chip design in 2022, initially launched the B1L product featuring the Darkbird 1.0 chip for BTC mining. This was followed by the first-generation V1 Series, powered by the Cuckoo 2.0 chip for ETH mining.
Recently, on November 18, Nano Labs received a notification letter from the Listing Qualifications Department of Nasdaq indicating that it has regained compliance with the <a target="_blank" href="https://www.benzinga.com//node/42075274" rel="noreferrer noopener">minimum bid price requirement.</a>
Also, earlier this week, Nano Labs revealed its intention to allocate some excess liquidity to Bitcoin and hold it as a <a target="_blank" href="https://www.benzinga.com//node/42034251" rel="noreferrer noopener">long-term strategic reserve asset.</a>
Price Action: NA shares are trading higher by 52.9% to $6.68 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42124676/november-small-cap-surge-could-carry-into-decembers-santa-rally-historical-trends-suggest" target="_blank" rel="noreferrer noopener">November Small-Cap Surge Could Carry Into December's Santa Rally, Historical Trends Suggest</a></li>
</ul>

Equities

Movers

General

Chinese Fabless Integrated Circuit Company Nano Labs Stock Skyrockets With New V Series Launch: Details

<a href="https://www.bloomberg.com/news/articles/2024-11-22/facebook-appeal-over-shareholder-suit-dropped-by-supreme-court">https://www.bloomberg.com/news/articles/2024-11-22/facebook-appeal-over-shareholder-suit-dropped-by-supreme-court</a>
&nbsp;
The US Supreme Court dismissed an appeal by <a href="https://www.bloomberg.com/quote/META:US">Meta Platforms Inc.</a>, leaving it to face a lawsuit that accuses the company of misleading shareholders about the data-harvesting scandal involving political consulting firm <a href="https://www.bloomberg.com/quote/1584842D:LN">Cambridge Analytica</a>.
Investors claim the company, then known as Facebook, inflated share prices by failing to adequately disclose the risk that its user data would be misused. The shareholders say revelations about the scandal contributed to two 2018 price drops that cost the company more than $200 billion in market value.

Legal

'Meta Must Face Investor Suit After Supreme Court Drops Case; Company Faces Allegations Over Data-Harvesting Scandal; Supreme Court Heard Arguments On Meta's Appeal On Nov. 6' - Bloomberg News

Trump Media &amp; Technology Group Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) boasts an 82.88% gain over the past year. Yet recent months have tested the resolve of its bulls, with a 30.17% dip over six months and a 9.45% slide <a href="https://www.benzinga.com/topic/donald-trump">in the last month</a>.
The Truth Social parent company is now exploring a cryptocurrency payment service, TruthFi, as <a href="https://www.ft.com/content/d7f921d5-3668-4b6b-a98d-2681ad73610f">reported</a> by the Financial Times. 
Is this the diversification move the stock needs to regain its upward momentum?
Read Also: <a href="https://www.benzinga.com/general/social-media/24/11/42124007/trump-media-trademark-filing-for-truthfi-hints-at-potential-digital-wallets-asset-trading">Trump Media Trademark Filing For &#8216;TruthFi&#8217; Hints At Potential Digital Wallets, Asset Trading</a>
<h2 class="wp-block-heading">DJT Stock Chart: Bulls &amp; Bears Playing Tug-O-War</h2>
DJT's technical indicators paint a mixed picture. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22103058/Screenshot-2024-11-22-at-9.00.42-PM.png" alt="" class="wp-image-661165" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22103058/Screenshot-2024-11-22-at-9.00.42-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22103058/Screenshot-2024-11-22-at-9.00.42-PM-300x234.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112224&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
DJT stock, at $30.77, sits above its eight-day simple moving average (SMA) of $29.75, offering a short-term bullish signal. 
Yet, its 20-day SMA of $33.53 looms as a resistance point, giving a bearish signal. The 50-day SMA at $26.60 reinforces a bullish undertone for the intermediate term, but the 200-day SMA at $34.45 suggests broader bearish pressure.
Momentum indicators add complexity: the moving average convergence/divergence (MACD) indicator sits at 0.18, a bullish signal, while the relative strength index (RSI) at 50.16 hovers in neutral territory. 
DJT stock traders are likely watching closely for any confirmation of a breakout or breakdown from these levels.
<h2 class="wp-block-heading">TruthFi: Crypto Catalyst Or Diversification Dilemma?</h2>
Trump Media's trademark application for TruthFi hints at ambitions to leverage the crypto wave. If launched, TruthFi could extend beyond payment processing to include trading and asset management, positioning DJT as more than a social media play. The nascent nature of these plans — compounded by broader market skepticism — leaves the timeline and impact uncertain.
Trump Media is also reportedly interested in buying Bakkt. Shares of the crypto custody startup skyrocketed 160% on the rumors, but no concrete deal has materialized.
President-elect Donald Trump's signaling of crypto-friendly regulation will likely benefit DJT stock as well. 
<h2 class="wp-block-heading">What's Next For DJT Stock?</h2>
While bulls may see Trump Media's entry into crypto as the next growth catalyst, bears argue the stock's technical resistance and uncertain fundamentals warrant caution. 
For now, traders find themselves at an inflection point, waiting to see whether TruthFi's promise can materialize into profits — and whether DJT can move the needle in either direction.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42071926/a-hedge-fund-hit-big-on-trumps-rumored-crypto-acquisition-and-is-up-1415-million">A Hedge Fund Hit Big On Trump&#8217;s Rumored Crypto Acquisition And Could Be Up $14.15 Million</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Social Media

Technicals

Tech

Trump Media's TruthFi Gamble Tests Bulls And Bears

<a href="https://www.wsj.com/health/healthcare/sanofi-plans-to-change-hospital-drug-discount-program-18557f6d">https://www.wsj.com/health/healthcare/sanofi-plans-to-change-hospital-drug-discount-program-18557f6d</a>
&nbsp;
An industry fight against <a href="https://www.wsj.com/articles/340b-drug-discounts-hospitals-low-income-federal-program-11671553899?mod=article_inline&amp;mod=article_inline">lucrative drug discounts</a> for hospitals is intensifying as another drugmaker joins the battle: <a href="https://www.wsj.com/market-data/quotes/FR/XPAR/SAN">Sanofi</a>.
The pharmaceutical company plans to change its policy on how it gives discounts to certain hospitals. Sanofi will require institutions to provide pharmacy and medical claims information before receiving federally mandated discounts. The company plans to send a letter, which was reviewed by The Wall Street Journal, to hospitals outlining its new model on Friday, according to people familiar with the matter.&nbsp;

Biotech

'Sanofi Plans To Change Hospital Drug-Discount Program; French Company Looks To Rein In How It Gives Discounts In Federal Program Designed To Help Hospitals That Serve Low-income And Uninsured Patients' - WSJ

QMMM Shares Halted On Circuit Breaker To The Downside, Stock Now Up 30.3%

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler boosted the price target for Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) from $100 to $130. Piper Sandler analyst Rob Owens maintained an Overweight rating. Elastic shares closed at $109.21 on Thursday. <a href="https://www.benzinga.com/quote/ESTC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>RBC Capital cut the price target for Atkore Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>) from $99 to $93. RBC Capital analyst Deane Dray maintained a Sector Perform rating. Atkore shares closed at $85.14 on Thursday. <a href="https://www.benzinga.com/quote/ATKR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan cut Warner Music Group Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NYSE">WMG</a>) price target from $41 to $40. JP Morgan analyst David Karnovsky maintained an Overweight rating. Warner Music shares settled at $31.18 on Thursday. <a href="https://www.benzinga.com/quote/WMG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc boosted Procore Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>) price target from $68 to $85. Keybanc analyst Jason Celino maintained an Overweight rating. Procore Technologies shares closed at $75.23 on Thursday. <a href="https://www.benzinga.com/quote/PCOR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel cut DiamondRock Hospitality Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRH#NYSE">DRH</a>) price target from $10.75 to $10.25. Stifel analyst Simon Yarmak downgraded the stock from Buy to Hold. DiamondRock Hospitality shares closed at $9.14 on Thursday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark cut PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) price target from $185 to $160. Benchmark analyst Fawne Jiang maintained a Buy rating. PDD shares closed at $104.09 on Thursday. See how other analysts view this stock.</li>
<li>Truist Securities raised the price target for AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) from $119 to $129. Truist Securities analyst Jamie Cook maintained a Buy rating. AECOM shares settled at $112.56 on Thursday. <a href="https://www.benzinga.com/quote/ACM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer boosted Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) price target from $712 to $722. Oppenheimer analyst Scott Schneeberger maintained an Outperform rating. Intuit shares closed at $678.70 on Thursday. <a href="https://www.benzinga.com/quote/INTU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclay increased the price target for The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) from $31 to $32. Barclays analyst Adrienne Yih maintained an Overweight rating. Gap shares closed at $22.04 on Thursday. <a href="https://www.benzinga.com/quote/GAP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel cut Spire Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>) price target from $70 to $69. Stifel analyst Selman Akyol maintained a Hold rating. Spire shares closed at $70.66 on Thursday. <a href="https://www.benzinga.com/quote/SR/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42139477/this-hca-healthcare-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-friday">This HCA Healthcare Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday</a></li>
</ul>

ATKR

ESTC

INTU

PCOR

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Gap To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Friday

Oppenheimer analyst Ken Wong maintains Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Outperform and raises the price target from $300 to $350.

ADSK

Oppenheimer Maintains Outperform on Autodesk, Raises Price Target to $350

Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) stock fell 1.7% to $162.87 this week, as investors assessed the ripple effects of NVIDIA's <a href="https://www.benzinga.com/markets/24/11/42101875/nvidia-beats-q3-revenue-eps-estimates-supply-constraints-ding-stock-huang-says-age-of-ai-is-in-full">third-quarter earnings report</a> on the broader semiconductor sector.
Nvidia, a key player in AI and data center markets where Broadcom also operates, posted strong results but provided a cautious fourth quarter outlook. The mixed market reaction to Nvidia&#8217;s report appeared to keep Broadcom shares in a holding pattern, reflecting broader uncertainties about growth prospects in the chip industry.
What To Know: Nvidia's robust performance underscored the ongoing demand for AI-related infrastructure, including advanced GPUs and complementary hardware, areas where Broadcom's networking and connectivity solutions play a critical role. 
<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42119226/nvidia-analysts-see-stock-best-positioned-in-ai-not-worried-about-guidance-all-systems-go-for-blackwell-ramp">Analysts highlighted</a> Nvidia's next-generation Blackwell architecture as a significant driver of demand through 2025. However, Nvidia's guidance falling short of lofty expectations caused some profit-taking, illustrating the market&#8217;s sensitivity to growth narratives in the AI space.
Read Also: <a href="https://www.benzinga.com/24/11/42137117/teslas-balancing-act-us-china-trade-tensions-what-it-means-for-tsla-stock">Tesla Gains 55% In A Month With Strong China Role, Bullish Signals</a>
Broadcom, a major supplier of chips for data centers and AI workloads, is often viewed as a complementary player to Nvidia, benefiting from the surge in demand for high-performance computing infrastructure. 
Investors have also been closely watching Broadcom's strategic moves in recent memory, particularly its ongoing diversification efforts, including its <a href="https://www.benzinga.com/m-a/24/07/39692197/broadcom-issues-5b-in-debt-to-fund-vmware-acquisition">$61 billion acquisition</a> of VMware. 
This deal could further strengthen Broadcom's position in software-defined infrastructure, enhancing its ability to serve hyperscale data centers.
While Nvidia&#8217;s earnings highlighted sector strength, it also raised questions about near-term growth pacing. For Broadcom, the focus remains on its ability to capture a share of this evolving demand while leveraging its diverse portfolio.
Read Also: <a href="https://www.benzinga.com/news/econ-s/24/11/42138717/dollar-hits-2-year-highs-as-europes-recession-signals-spark-euro-pound-sell-offs">Dollar Hits 2-Year High As European Recession Fears Hammer Euro, Pound</a>
<h2 class="wp-block-heading">How To Buy AVGO Stock?</h2>
By now you're likely curious about how to participate in the market for Broadcom &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, AVGO has a 52-week high of $186.42 and a 52-week low of $90.31.

AVGO

What's Going On With Broadcom (AVGO) Stock?

BMO Capital analyst Thanos Moschopoulos maintains Real Matters (TSX:<a class="ticker" href="https://www.benzinga.com/stock/REAL#TSX">REAL</a>) with a Market Perform and lowers the price target from C$7.5 to C$7.

TSX:REAL

BMO Capital Maintains Market Perform on Real Matters, Lowers Price Target to C$7

Trading Halt: Halt status updated at 11:25:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

RBC Capital analyst Ben Hendrix reiterates SelectQuote (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLQT#NYSE">SLQT</a>) with a Sector Perform and maintains $4 price target.

Reiteration

SLQT

RBC Capital Reiterates Sector Perform on SelectQuote, Maintains $4 Price Target

BMO Capital analyst Jeffrey Silber maintains KinderCare Learning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLC#NYSE">KLC</a>) with a Outperform and lowers the price target from $34 to $31.

BMO Capital Maintains Outperform on KinderCare Learning, Lowers Price Target to $31

Nomura analyst Bing Duan upgrades Kingsoft Cloud Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) from Neutral to Buy and raises the price target from $2.3 to $6.7.

Upgrades

Nomura Upgrades Kingsoft Cloud Hldgs to Buy, Raises Price Target to $6.7

BMO Capital analyst Evan David Seigerman maintains Replimune Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) with a Outperform and raises the price target from $14 to $18.

REPL

BMO Capital Maintains Outperform on Replimune Group, Raises Price Target to $18

Andrew Hones, CEO and founder of New Market Capital, unveiled &#8220;Battery Finance&#8221; on CNBC on Friday—an asset management platform combining <a href="https://www.benzinga.com/news/events/24/11/42069387/grant-cardone-calls-himself-a-coward-investor-puts-his-money-in-real-assets">traditional assets like real estate</a> with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>).
What Happened: In an <a href="https://www.youtube.com/watch?v=26bOawTzT5U">appearance</a> on Squawk Box, Hones announced a loan that blends a 63-unit multi-family property in Philadelphia with Bitcoin as collateral. 
A $2 million loan was issued to refinance the existing mortgage on the property, fund improvements and allocate funds for purchasing Bitcoin. 
The loan combines traditional real estate collateral with Bitcoin, diversifying risk.
Borrowers must hold Bitcoin in escrow for at least four years, ensuring stability. 
The crypto king adds a hedge against inflation and enhances asset protection compared to traditional loans reliant solely on property.
Borrowers can repay loans anytime without penalty, but Bitcoin collateral remains locked for four years. 
Hones noted that this hybrid approach pairs stable, cash-flowing assets with Bitcoin&#8217;s growth potential, creating a hedge against volatility.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42138947/bitcoin-zeroes-in-on-100000-but-this-indicator-signals-one-more-brief-correction">Bitcoin Zeroes In On $100,000, But This Indicator Signals One More Brief Correction</a>
Why It Matters: Hones believes Bitcoin can complement fixed-income portfolios and address pension fund shortfalls. 
Over the medium to long term, Bitcoin's performance offers the potential for significant returns—its worst historical return over any four-year period stands at 23%.
This approach aims to reduce reliance on high-risk credit investments while narrowing asset-liability mismatches in pension portfolios. 
By integrating Bitcoin with traditional credit structures, Hones envisions a transformative investment strategy capable of reducing pension funding gaps and enhancing overall portfolio stability.  
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42127938/bitcoin-analyst-warns-of-4-6-flash-crashes-before-year-end-as-it-inches-closer-to-100k-thats-the-moment-altcoins-shoot-off">Bitcoin Analyst Warns Of &#8216;4-6 Flash Crashes&#8217; Before Year-End As It Inches Closer To $100K: That&#8217;s The Moment Altcoins &#8216;Shoot Off&#8217;</a></li>
</ul>
Image: Shutterstock

$BTC

Bitcoin Paying For Your Mortgage? One Company Enables It, But There's A Catch

QMCO

Quantum Shares Halted On Circuit Breaker To The Upside, Stock Now Up 105.5%

Oncternal Therapeutics Q2 2024 Earnings Preview

Oncternal Therapeutics GAAP EPS of -$2.89 beats by $0.14, revenue of $0.8M beats by $0.64M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Oncternal Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/onct-stock-quote/">ONCT</a>) just reported results for the second quarter of 2024.<ul><li>Oncternal Therapeutics reported earnings per share of -$2.89. This was above the analyst estimate for EPS of -$3.10.</li><li>The company reported revenue of $801,000.</li><li>This was 233.75% better than the analyst estimate for revenue of $240,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/onct-stock-earnings-oncternal-therapeutics-for-q2-of-2024/">ONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q2 2024

Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript

Oncternal plunges on portfolio shakeup

Oncternal Therapeutics ( ($ONCT) ) has shared an announcement. Oncternal Therapeutics, Inc. is reducing its workforce by 37%, approximately 10 empl...

Oncternal Therapeutics Restructures Amid Clinical Setbacks

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Oncternal Therapeutics (ONCT) has disclosed a new risk, in the Employment / Personnel category. Oncternal Therapeutics faces potential risks associ...

Oncternal Therapeutics Faces Workforce Reduction Challenges: Potential Risks and Implications

Oncternal Therapeutics ( ($ONCT) ) has provided an update. Oncternal Therapeutics, Inc. is undergoing a significant workforce reduction, effective ...

Oncternal Therapeutics Announces Workforce Reduction and Executive Changes

Oncternal Therapeutics ( ($ONCT) ) has released its Q3 earnings. Here is a breakdown of the information Oncternal Therapeutics presented to its inv...

Oncternal Therapeutics Reports Q3 2024 Earnings

ALLK

APVO

CNSP

CYCC

GNPX

IMUX

MBIO

ONCT

SYRS

Press Releases

Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results

Earnings

Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

Health Care

Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics to Present in JonesTrading Healthcare Summit

Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results

Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results

Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives

Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Comments

Oncternal Therapeutics

Notizie

Ultime notizie per Oncternal Therapeutics (NASDAQ:ONCT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO